ALG-001075, a capsid assembly modulator (CAM), is an orally active inhibitor of HBV. It effectively suppresses HBV DNA production in primary human hepatocytes and significantly reduces extracellular levels of HBsAg/HBeAg and intracellular HBV RNA. In AAV-HBV mouse models, ALG-001075 notably decreases HBV DNA levels. It can be utilized in research related to chronic hepatitis B (CHB).

ALG-001075 (Compound 10) effectively suppresses HBV DNA production in HepG2.117 cells at concentrations ranging from 0.01 to 1000 nM, with an EC50 of 0.63 nM and an EC90 of 3.17 nM. In primary human hepatocytes, ALG-001075 not only inhibits HBV DNA synthesis with an EC50 of 1.98 nM but also significantly reduces extracellular HBsAg (EC50 = 70 nM), HBeAg (EC50 = 10.5 nM), and intracellular HBV RNA levels (EC50 = 54.7 nM).

In an AAV-HBV mouse model, ALG-001075 (Compound 10) administered orally at 15-50 mg/kg twice daily for 56 days significantly reduced HBV DNA levels.